Audrey Jones
Family Medicine · Alamo, TXNPI 1699956748
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Novo Nordisk at 38.2% of the total. Reporting peaked in 2021 at $113 and has fallen 59.4% since, to $46 in 2025. That places this record below the midpoint for family medicine clinicians in TX, where the typical reported total is $436.
Across 7 payments — averaging $42.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$113
- Bayer$91
- Pfizer$32
- Medline Industries LP$31
- Abbott$29
Across 293 payments — averaging $3566.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$316K
- Astrazeneca UK Limited$212K
- Eisai Inc.$125K
- Bayer$121K
- Novartis$110K
- GSK$80K
- plus $81K from 7 others
What the payments were for
- Food & beverage$296100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 1 | $113 |
| Bayer | 1 | $91 |
| Pfizer | 2 | $32 |
| Medline Industries LP | 1 | $31 |
| Abbott | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$113
How this compares
$296 in reported general payments places this provider in the 40th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $45,535 |
| EliquisApixaban | 15 | $22,314 |
| FarxigaDapagliflozin Propanediol | 29 | $22,000 |
| JardianceEmpagliflozin | 16 | $19,291 |
| MounjaroTirzepatide | 12 | $17,463 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $4,540 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $3,782 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $1,720 |
| Rosuvastatin Calcium | 176 | $1,651 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,248 |
| Levothyroxine Sodium | 144 | $1,243 |
| Hydroxychloroquine Sulfate | 16 | $1,196 |
| Gabapentin | 40 | $1,177 |
| Fentanyl | 13 | $1,168 |
| Losartan Potassium | 99 | $1,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $113 | $45,53527 claims |
| PfizerEliquis | $32 | $22,31415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Alamo
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.